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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT 
 
Nelfinavir is an HIV protease inhibitor, substrate of the transporter P-glycoprotein and 
metabolized via CYP2C19, CYP3A4 and CYP3A5 enzymes. Pharmacokinetic studies 
showed a wide interindividual variability of nelfinavir concentrations, some of this 
variability may be caused by variant drug metabolism or transporter genes. For 
CYP3A4*1B and CYP3A5*3 polymorphism, results from 3 studies were in agreement, 
showing no difference in nelfinavir concentrations between patients with these 
different genotypes. However, for MDR1 and CYP2C19 polymorphism, contradictory 
studies were found, showing either no impact on nelfinavir concentration or modified 
concentrations which could influence virologic response.  
 
WHAT THIS STUDY ADDS –  
 
Patients with an *1/*2 or *2/*2 genotype for CYP2C19 had a nelfinavir to M8 
biotransformation divided by 2 compared to *1/*1 patients. We did not evidence any 
influence of MDR1 polymorphism on nelfinavir absorption.  
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Abstract 
Aims : To evaluate the effect of CYP2C19 polymorphism on nelfinavir and M8 
pharmacokinetic variability in HIV infected patients and to study the link between 
pharmacokinetic exposure and short term efficacy and toxicity. Methods: Nelfinavir 
(n=120) and M8 (n=119) concentrations were measured in 34 protease inhibitor 
naive-patients. Two weeks after initiating the treatment, blood samples were taken 
before, 1, 3 and 6 hours after drug administration. Genotyping for CYP3A4, 3A5, 
2C19 and MDR1 was performed. A population pharmacokinetic model was 
developed to describe nelfinavir-M8 concentration time-courses and to estimate inter-
patient variabilities. The influence of individual characteristics and genotypes were 
tested using a likelihood ratio test. Estimated mean (C
mean
), maximal (C
max
) and 
trough (C
trough
) nelfinavir and M8 concentrations were correlated to short term 
virological efficacy and tolerance using Spearman nonparametric correlation tests. 
Results: A one-compartment model with first-order absorption, elimination and 
metabolism to M8 best described nelfinavir data. M8 was modelled by an additional 
compartment. Mean pharmacokinetic estimates and the corresponding inter-subject 
variabilities were: absorption rate 0.17 h
-1 
(99%), absorption lag time 0.82 h, apparent 
nelfinavir total clearance 52 L/h (49%), apparent nelfinavir volume of distribution 191 
L, M8 elimination rate constant 1.76 h
-1
 and nelfinavir to M8 
m
m
V
CL
 0.39 h
-1
 (59%) in 
*1/*1 patients and 0.20 h
-1
 in *1/*2 or *2/*2 patients for CYP2C19*2. Nelfinavir C
mean
 
was positively correlated to glycemia and triglycerides increases (p=0.02, p=0.04). 
Conclusions: The rate of metabolism of nelfinavir to M8 was reduced by 50% in 
patients with *1/*2 or *2/*2 genotype for CYP2C19 compared to those patients with 
*1/*1 genotype. 
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Introduction 
         Nelfinavir is a protease inhibitor commonly used as a part of the highly active 
antiretroviral therapy for human immunodeficiency virus infected patients. The use of 
protease inhibitor-based regimen led to substantial decrease in viral load and 
restoration of immune function in most HIV-positive individuals, permitting a decline 
in death rates, and reductions in the incidence of opportunistic infections [1, 2]. 
Nelfinavir bioavailability is between 70 and 80 % when administered with food [3]. In 
the intestine, P-glycoprotein (P-gp) restricts the entry into the body of nelfinavir which 
is a substrate of this transporter [4]. The volume of distribution is 2 to 7 L/kg of 
bodyweight. Nelfinavir is metabolized into the active metabolite hydroxyl-tert-
butylamide (M8) via the CYP2C19 enzyme, and both drugs are metabolized via 
CYP3A4 [5, 6]. Nelfinavir is the only HIV protease inhibitor that has an active 
metabolite (M8) present in potentially therapeutic concentrations [6].  
 
          There is a wide interindividual variability in the disposition of this drug, and 
some of this variability may be caused by variant drug metabolism or transporter 
genes. Some studies were already performed to study the impact of CYP3A4, 
CYP3A5, CYP2C19 and MDR1 polymorphism on nelfinavir pharmacokinetics. A 
single-nucleotide polymorphism in the 5’ regulatory region of CYP3A4 gene (A-392 G) 
named CYP3A4*1B is the most common variant; it has been associated in vitro with 
enhanced CYP3A expression [7]. The CYP 3A5*3 polymorphism (A6986 G) leads to 
an inactive truncated protein [8]. However Fellay et al. [9], Saitoh et al. [10] and Haas 
et al. [11] did not evidence any differences in nelfinavir concentrations between 
patients with these different genotypes. Concerning the effect of MDR1 
polymorphism, conflicting results have been found. Two singles nucleotide 
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polymorphism in MDR1-gene G2677A/T in exon 21, and C3435T in exon 26 were 
shown to be associated with variation in P-gp expression. Fellay et al. [9] showed an 
increase in median nelfinavir concentration for patients MDR1 3435 from TT, CT to 
CC genotypes. Saitoh et al. [10] found that children with CT genotype for MDR1 3435 
had higher 8h postdose nelfinavir concentration compared to those with other 
genotypes. However Haas et al. [11] did not evidence any influence of the MDR1 
polymorphism in exon 26 and 21 on nelfinavir AUC. For CYP2C19 gene, CYP2C19*2 
(G681A point mutation in exon 5) is the most common variant in Caucasian, which 
has no enzyme activity. Haas et al. [11] found in 348 HIV infected adults, that 
patients *1/*2 (AG) or *2/*2 (AA) had significantly higher nelfinavir and nelfinavir plus 
M8 AUC
0-12h
 than
 
*1/*1 (GG) genotype and tended to have a better virologic 
response. However Fellay et al. [9] in 123 adults, Saitoh et al. [10] in 71 children and 
Burger et al. [12] in 24 adults did not find any effect of the CYP2C19 genotype on 
nelfinavir concentrations in plasma.    
The aims of this study were to evaluate the influence of genetic polymorphism on 
pharmacokinetic parameters (MDR1 on absorption, CYP2C19 on nefinavir to M8 
biotransformation and CYP3A4 on nelfinavir and M8 metabolism) and to correlate 
concentrations to short term virological efficacy and toxicity.  
 
Methods 
Patients 
The COPHAR2-ANRS 102 study was an open, multicenter, prospective trial of HIV1 
infected adults who started a treatment with an antiretroviral combination of at least 
three drugs : 2 nucleoside reverse transcriptase inhibitors plus one protease inhibitor; 
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either nelfinavir, or indinavir or lopinavir. In our group, all patients were administered 
nelfinavir.  
Patients older than 18 years, infected by HIV-1, protease inhibitor-naive were eligible. 
The Ethical Review Committee of the Bicêtre Hospital, Paris, France reviewed and 
approved the study protocol. All participants provided written informed consent.  
These adults were administered nelfinavir as 1250 mg twice daily (BID), only one 
patient had 1500 mg twice daily and one had a 625 mg twice daily. Nelfinavir was 
given using the new formulation of 625 mg tablets [13]. A 250 mg tablet was added 
for the patient who received 1500 mg BID. A blood sample was taken for genotype 
before initiating the treatment and two weeks later patients underwent 4 blood 
samplings, before, 1, 3 and 6 hours after drug intake for pharmacokinetic analysis. 
For each patient, time elapsed between administration and sampling times were 
carefully recorded. For modeling, we assumed that patients were at steady state with 
a dosing interval τ of 12 h. The trough concentration was the concentration measured 
the day before drug intake and the 3 other concentrations were measured after drug 
intake. 
Short term efficacy was studied using HIV RNA levels at day 0 and week 2. Short 
term tolerance (fasten cholesterol, triglyceride and glycemia) was analyzed, based on 
measurements performed 4 weeks before and 4 weeks after initiating the treatment. 
A questionnaire for adherence was also used. One adherence covariate was 
analyzed, corresponding to the yes/no answer at the question “During the last 4 days, 
did you forget or delay deliberately or not your antiretroviral drug intake?” 
 
Analytical method 
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Nelfinavir and M8 plasma concentrations were measured by specific high 
performance liquid chromatography. The 4 participant laboratories were cross-
validated before starting the study. Results of the blind interlaboratory quality control 
at three concentrations for nelfinavir and for M8 were within 15% of the target values 
from medium and high values and within 20% for low values. Lower limits of 
quantification (LOQ) were 100 ng/mL for nelfinavir and 25 ng/mL for M8 depending 
on the method used.  
 
Genotyping 
All Genotypes were performed in the same laboratory. Total deoxyribonucleic acid 
(DNA) was extracted from plasma samples by use of the QIAamp DNA Blood Mini Kit 
(Qiagen, Courtaboeuf, France). Genotyping for CYP2C19*2 was performed by a 
polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) 
method with allele-specific primers, as described by de Morais et al. [14]. Genotyping 
for CYP3A4*1B was determined by polymerase chain reaction (PCR) followed by 
direct sequencing. PCR was performed by use of a GenAmp PCR System 9700 
(Applied Biosystems, Courtaboeuf, France) according to a previously published 
method [15]. Amplified DNA was purified by use of the QiaQuick DNA Purification 
System (Qiagen) and sequenced by use of BigDye Terminator chemistry and an ABI 
PRISM 3100 genetic analyzer (Applied Biosystems). Genotyping of CYP3A5*3 and 
*6 was performed by real-time polymerase chain reaction by use of TaqMan MGB 
probe technology (Applied Biosystems). MDR1 polymorphisms in exons 21 and 26 
were determined by use of previously published methods [16].  For each genotyping 
analysis, at least 2 positive controls were used: 1 homozygous for the wild-type allele 
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and 1 heterozygous and, when available, 1 homozygous for the mutated allele. 
These controls are DNAs that have been sequenced. 
 
 
Modelling strategy and population pharmacokinetic model 
Data were analyzed using the nonlinear mixed effect modelling software program 
NONMEM (version V, level 1.1, double precision) with the DIGITAL FORTRAN 
compiler [17]. The first-order conditional estimation (FOCE) with interaction method 
was used. A one-compartment model with first-order absorption, elimination and 
metabolism to M8, best described nelfinavir data. M8 was modelled by an additional 
compartment (Fig 1). Parameters of the model were the bioavailability (F), the 
absorption rate constant (k
a
), the absorption lag time (Tlag), the volumes of 
distribution of nelfinavir and M8 (V and V
m
), the total elimination rate constant for 
nelfinavir (k corresponding to k
e
+k
m
 in Fig 1), the metabolic rate constant (k
m
) 
describing the nelfinavir to M8 biotransformation, and the elimination rate constant for 
M8 (k
em
). Since nelfinavir was orally administered, only k
a
, Tlag, V/F and k were 
identifiable for nelfinavir. For M8, since no urinary concentration data were available, 
and because no literature data were used to fix V
m
/F, only Fk
m
/V
m
 and k
em
 could be 
determined. Therefore, the model was reparametrized using an apparent clearance 
for nelfinavir (CL
T
/F = k x V/F) and an apparent nelfinavir to M8 biotransformation 
clearance (CL
m
/F = k
m
 x V/F). The vector of identifiable parameters used in the 
population analysis was therefore ka, Tlag, CL
T
/F, V/F, 
m
m
V
CL
and k
em
.   
The following equations describe nelfinavir and M8 plasma concentrations: 
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with t = delay-Tlag   if delay >Tlag                and           t = delay-Tlag + τ if delay<Tlag,  
where t is the calculated time between start of absorption and sampling, Tlag is the 
estimated absorption lag time, delay is the recorded time elapsed between drug 
administration and blood sampling and τ is the time interval between 2 
administrations. 
When nelfinavir or M8 concentrations were below the LOQ, we set them to half of the 
LOQ. Several error models were investigated (i.e. multiplicative and additive error 
models) to describe residual variability. Proportional model was used for inter-subject 
variability (ISV). Data for nelfinavir and M8 were then fitted jointly. Only significant 
ISVs on pharmacokinetic parameter were kept, i.e. a minimum of 3.84 unit decrease 
using a likelihood ratio test in a backward elimination procedure. From the 
POSTHOC option of NONMEM applied on this basic model, Empirical Bayes 
estimates of each parameter were obtained. The effect of each patient covariate was 
tested on these estimates, using Spearman nonparametric correlation test for 
 10 
continuous covariates such as age, bodyweight, body mass index, albumine and 
orosomucoid or using the Wilcoxon test for categorical ones such as sex, CDC stade 
of virus infection (C/non C), genotypes (CYP3A4*1B, CYP3A5*3 and *6, CYP2C19*2, 
MDR1 exon21, MDR1 exon 26), adherence and the co-administration of combivir
®
 
(drug combining AZT and 3TC). Co-medication was analyzed in 2 classes: patients 
who were taking combivir
®
 against other co-medications. Genetic polymorphism was 
analyzed in two different ways: wild type against heterozygote plus homozygote 
mutated or wild type plus heterozygote against homozygote mutated. Covariates that 
were found to have an effect on a pharmacokinetic parameter with a p value lower 
than 0.10, were retained for inclusion in the population model. They were then added 
one by one to the basic pharmacokinetic model, the most significant at first. 
Continuous covariates (CO) were tested according to the following equation, using 
CL for example,
CL
CO
β
CL
)
median(CO)
CO
(θCL ×=
, where  θ
CL
 is the typical value of 
clearance for a patient with the median covariate value and 
 
CL
CO
β is the estimated 
influential factor for the continuous covariate. Categorical covariates (CA) were tested 
as, CA)β/(1θCL
CL
CACL
×+=  where CA=0 or 1. Patients with a missing value for a 
covariate retained during the first statistical analysis were excluded of the covariate 
population modeling. The basic model was fitted again with the patients with all 
covariate values and the covariate could then be tested. 
A covariate was kept if its effect was biologically plausible; it produced a minimum 
reduction of 3.84 in the objective function value (OFV) and a reduction in the 
variability of the pharmacokinetic parameter, assessed by the associated inter-
subject variability. An intermediate model with several covariates was then obtained. 
All the selected covariates were added one by one and kept if responding to the cited 
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3 criteria.  At the end of this ascendant modeling, the final model was obtained. A 
backward elimination phase was finally performed by deleting each covariate from 
the final model in order to calculate the p value, using a likelihood ratio test.  
For evaluation of the goodness-of-fit, the following graphs were performed: 
observed and predicted concentrations versus time, observed concentrations vs 
population predictions, weighted residuals vs time and weighted residuals vs 
predictions. Similar graphs using individual predictive POSTHOC estimation were 
displayed. Diagnostic graphics were obtained using the R program [18].  
 
 
Validation.  
Nelfinavir and M8 steady-state concentration profiles were simulated and compared 
with the observed data thanks to visual predictive check in order to evaluate the 
performance of the model. More precisely, the vector of pharmacokinetic parameters 
from 1000 patients was simulated using the final model. Each vector parameter was 
drawn in a normal distribution with a variance corresponding to the ISV previously 
estimated. A simulated residual error was added to each simulated concentration.  
The simulations were performed using NONMEM. The 5
th
, 50
th
 and 95
th
 percentiles of 
the simulated concentrations at each time were then overlaid on the observed 
concentration data using R program and a visual inspection was performed.  
  
Links between concentrations and short term response / toxicity.  
For each patient, mean (C
mean,N
), maximal (C
max,N
) and trough (C
trough,N
) nelfinavir 
plasma concentrations and the sum of nelfinavir + M8 trough (C
trough,NM8
) plasma 
concentrations were derived from the estimated individual pharmacokinetic 
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parameters. The efficacy was studied following the difference in log viral load 
between the day of initiation treatment and week 2. The significance of the viral load 
decrease was first tested using a wilcoxon non-parametric paired test. With respect 
to efficacy, the links between C
trough,N
 , C
trough,NM8
 and the difference in HIV-1 RNA 
level between day 0 and Week 2 was evaluated using correlation Spearman tests. A 
Wilcoxon non-parametric test was also performed on decrease in viral load between 
patients having or not a C
trough
 below the lower limit of therapeutic range (1500 ng/mL, 
limit used in the COPHAR 2-ANRS 111 trial).  
Toxicity was analyzed from the difference between 4 weeks after and before 
treatment initiation in total cholesterol, high density lipoprotein cholesterol, triglyceride, 
glycemia and from appearances of diarrheas (grade 2) between treatment initiation 
and week 4. The significance of these differences was tested using a Wilcoxon non-
parametric paired test. Then we performed correlation Spearman tests between 
C
mean,N
, C
max,N
, C
trough,N
 and difference in total cholesterol, high density lipoprotein 
cholesterol, triglyceride and glycemia.  We also used Wilcoxon non-parametric tests 
to compare these differences between patients having or not a C
trough
 over the upper 
limit defined in the therapeutic index (5500 ng/mL, limit used in the COPHAR 2-
ANRS 111 trial). 
We also assessed the relationship between the genetic polymorphisms remaining in 
the final population model and C
mean,N
, C
max,N
, C
trough,N
 and the relationship between 
these genetic polymorphisms and the efficacy and toxicity outcomes previously 
described, using Wilcoxon non-parametric tests.  
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Results 
Demographic data 
Thirty four patients were included in the nelfinavir arm. All these patients were 
available for pharmacokinetic evaluation. A total of 120 nelfinavir concentrations and 
119 M8 concentrations were collected. Table 1 summarizes patient characteristics: 
age, bodyweight, BMI, orosomucoid, albumin, sex, CDC stage, concomitant 
medications with combivir ®, good adherence and genetic polymorphism for genes 
MDR1 (exon 21 and 26), CYP2C19, CYP3A4, CYP3A5.  
 
Population pharmacokinetics : Nelfinavir-M8 pharmacokinetic model building. 
One nelfinavir and 13 M8 concentrations were lower than the LOQ, so they were set 
to half of the LOQ. Inter-subject variability was described by multiplicative model. The 
available data were not sufficient to estimate inter-subject variability for Tlag, V/F and 
k
em
, and fixing the variance of these random effects to zero had no influence on the 
objective function values (OFV). Residual variabilities were best described by 
proportional error model. The addition of a correlation between nelfinavir and M8 
residual variabilities (r= 0.37 (40%)) decreased OFV by 8.45 units.  
Covariates were first tested on Bayesian Empiric estimates of Ka, CL/F and CL
m
/V
m
 
from the basic model. The most significant covariate was for CYP2C19 genotypes on 
CL
m
/V
m
, a significant difference was found between wild type (*1/*1, GG) and other 
patients (*1/*2, AG or *2/*2, AA) (p=0.01). The coadministration of combivir ® 
increased significantly k
a
 (p=0.02). Four patients did not have a genotype for the 
CYP2C19, so they were excluded from the covariate modeling and a basic model 
was fitted again with the remaining 30 patients. Then, CYP2C19 genotype was first 
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added on 
m
m
V
CL
 as an inhibitory effect for patients with the mutation. The effect was 
significant resulting in 7.03 units decrease in the OFV, in a 13 % decrease in the 
inter-subject variability of CL
m
/V
m
, and a better correlation between observed and 
predicted concentrations. The coefficient 
m
m
V
CL
CYP2C19
β  was equal to 0.98, meaning that the 
rate of metabolism of nelfinavir to M8 was reduced by 50% in patients with *1/*2 or 
*2/*2 genotype for CYP2C19 compared to those patients with *1/*1 genotype.  
Then combivir ® coadministration was added on K
a
 in this intermediate model, but no 
significant effect was found. Figure 2 displays nelfinavir and M8 observed and 
predicted plasma concentrations at week 2 versus time, for CYP2C19 wild type 
(patients GG for CYP2C19*2) and for CYP2C19 mutated patients (AG or AA for 
CYP2C19*2). Table 2 summarizes the final population pharmacokinetic estimates in 
30 patients.  
 
Model performance. Final model performance were appreciated by comparing 
population predicted and individual predicted to observed plasma concentrations and 
population weighted residuals versus predicted concentrations and versus time for 
nelfinavir and for M8. Visual predictive check of the final population PK model (Fig 3) 
showed the comparison between the 5
th
, 95
th
 and 50
th
 predicted percentiles for the 
1000 simulations and the observed concentrations of nelfinavir. This evaluation 
method provided good proof for the model adequacy. 
 
 
 
 
 15 
Links between concentrations and short term response / toxicity.   
The values of the following parameters: HIV-1 RNA level, total cholesterol, HDL 
cholesterol, glycemia and triglycerides were available for 30 patients as basal, and as 
2 or 4 weeks treatment which allowed to calculate their variation and to test the 
significance of the difference.      
The viral load decreased significantly after 2 weeks of treatment (table 3). However 
the significant decrease in HIV-1 RNA between day 0 and Week 2 was not correlated 
to C
trough,N, 
nor to C
trough,NM8
 and was not different between patients with a C
trough
 
below or above  the lower limit of therapeutic range of 1500ng/ml.  
Total cholesteol increased significantly after 4 weeks of treatment, contrarily to HDL 
cholesterol (Table 3). Nelfinavir C
trough,N
, C
max,N
 and C
mean,N
 were not significantly 
correlated with total nor with HDL cholesterol evolution. Glycemia increased after 4 
weeks of treatment (p=0.05) and its evolution was significantly positively correlated to 
nelfinavir C
mean,N
 and C
trough,N
 (p=0.02 and p=0.03). Although triglycerides increase 
was not significant, its evolution was significantly positively correlated to nelfinavir 
C
mean,N
 (p=0.04) (Fig 4). No patient had a C
trough
 over the therapeutic index upper limit 
of 5500 ng/mL. No grade 2 diarrhea was recorded. 
We could not evidence any significant differences in C
trough,N
 C
trough,NM8
, nor in short 
term efficacy or toxicity between patients *1/*1 and patients *1/*2 or *2/*2 for 
CYP2C19 gene.  
 
Discussion 
The concentrations of nelfinavir and of M8 were satisfactorily described by a one-
compartment model with first-order absorption and elimination for nelfinavir with an 
additional compartment for M8 linked with a first order rate constant. This joint model 
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was already used in adults [19, 20]. The following results support the use of this 
pharmacokinetic model: 
Nelfinavir mean plasma clearance was consistent with previously reported 
values: CL
T
/F
 
= 52 L/h compared to 37.3, 35.5 and 44.9 L/h obtained in Panhard et al. 
[19], in our previous [20] and in Jackson et al. [21] studies.  
Nelfinavir to M8 biotransformation and M8 elimination were consistent with our 
2 previous studies (in women and in children [20, 22]) and with Panhard et al. study 
[19], CL
m
/V
m
=0.39 h
-1
 compared to respectively 0.65, 0.58 and 0.36 h
-1
 and k
em
 = 
1.76 h
-1
 compared to 3.3, 1.88 and 1.93 respectively. 
Nelfinavir to M8 biotransformation was reduced in patients *1/*2 or *2/*2 for 
the CYP2C19 genotype compared to the wild type *1/*1 genotype which is consistent 
with Burger et al. [12] and Haas et al. [11] studies who found a significantly lower M8 
to nelfinavir AUC ratio in patients with the mutation than in wild type patients. In our 
study, no patients had liver dysfunction, and no one was taking concurrent 
medications that are potential inhibitors of CYP2C19, so the decrease in nelfinavir to 
M8 biotransformation could only be attributed to CYP2C19 polymorphism.  
 
A major aim of population pharmacokinetics is to determine which measurable 
pathophysiological factor can cause changes in the dose-concentration relationship. 
In this study, only the CYP2C19 genotype was found to influence nelfinavir and M8 
pharmacokinetics. Nelfinavir is metabolized exclusively by CYP2C19 into M8 [5]. 
Nelfinavir and M8 are described as being equally active [6]. Haas et al. [11] found in 
348 HIV infected adults, that patients *1/*2 or *2/*2 had significantly higher nelfinavir 
and nelfinavir + M8 AUC
0-12h
 than
 
*1/*1 genotype and tended to have a better 
virologic response. We could not evidence a significant difference in nelfinavir or 
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nelfinavir + M8 concentrations between the 2 genotypes. In this study, as we could 
estimate individual pharmacokinetic parameters, we could quantify the effect of 
CYP2C19 polymorphism directly on these parameters and have a mechanistic 
approach of the process. We found that the rate of metabolism of nelfinavir to M8 
was reduced by 50% in patients with *1/*2 or *2/*2 genotype for CYP2C19 compared 
to those patients with *1/*1 genotype. Moreover, as shown in Figure 2, M8 
concentrations were lower in patients *1/*2 or *2/*2 than in *1/*1 patients for 
CYP2C19, whereas nelfinavir concentrations were similar (Figure 2). This suggests 
an increase in nelfinavir elimination by CYP3A4 which compensate the decreased 
elimination via CYP2C19. Concerning CYP3A4 and MDR1 genes, in agreement with 
precedent studies [9, 10, 11], we did not evidence any difference between wild type 
and mutated groups for nelfinavir and M8 pharmacokinetics. 
           
         Powderly et al. [23] showed that change in viral load over the first 4 weeks of 
treatment was predictive of virological response over 48 weeks of treatment. 
Hoetelmans et al. [24] in 29 HIV infected, antiretroviral-naïve patients using a 
quadruple drug regimen (nelfinavir, saquinavir, stavudine and lamivudine) showed 
that median nelfinavir concentration ratio was positively correlated with the 
elimination rate constant (k) of HIV-1 clearance (k = slope of the curve describing 
initial log viral load as a function of time). We could not establish a significant 
relationship between nelfinavir concentrations and the reduction in HIV RNA level 
after 2 weeks of treatment in our PI naïve patients. The main difference with 
Hoetelmans et al. study was that the decrease in HIV RNA was much lower in our 
study: viral load was divided by 1.80 in 14 days, corresponding to an elimination rate 
constant for HIV-1 clearance of 0.13 day
-1
. In Hoetelmans study similar basal viral 
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load were measured but k was 0.29 day
-1
, indicating that median viral load was 
divided by 4 after two weeks of treatment.  
Few studies evaluated cholesterol, triglycerides and glycemia early changes as a 
function of nelfinavir plasma concentrations. As Périard et al. [25] who found that total 
cholesterol increased slightly but significantly (1.2 ± 0.2 mmol/L) after 4 weeks of 
treatment in 21 HIV-1 infected patients, we found a significant increase in total 
cholesterol in our 30 patients. However no relationship could be evidenced between 
this increase and nelfinavir plasma concentration. Similarly Reijers et al did not found 
any relationship between elevated cholesterol and plasma nelfinavir drug exposure, 
although the occurrence of elevated cholesterol was frequent i.e in 35% of their 
patients on quadruple regimen (stavudine, lamivudine, saquinavir and nelfinavir). 
Furthermore Reijers et al. [24] found that nelfinavir concentrations were not higher in 
hypercholesterolemic (>6.2 mmol/L), nor in hypertriglyceridemic (>4.5 mmol/L) 
patients. In our study, no patient had a triglycerides rate above 4.5 mmol/L, but a 
significant positive correlation was found between triglycerides rate and nelfinavir 
C
mean,N
 (p=0.04). We also found that nelfinavir C
mean,N
 and C
trough,N
 were significantly 
positively correlated with glycemia evolution (between 4 weeks after and before 
initiating the treatment) (p=0.02 and p=0.03).  
          
The rate of metabolism of nelfinavir to M8 was reduced by 50% in patients with *1/*2 
or *2/*2 genotype for CYP2C19 compared to those patients with *1/*1 genotype, 
without any significant modifications on nelfinavir trough concentrations, efficacy or 
toxicity. In these Pi-naïve patients, efficacy could not be related to nelfinavir plasma 
concentrations but triglycerides and glycemia increased with nelfinavir exposure.      
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Table 1.  Patient characteristics at baseline 
 
 
 
 
 
 
 
 Median Min Max 
Nb missing 
values 
Age (year) 31 19 63 0 
Bodyweight (kg) 67.25 51 88.5 0 
BMI (kg/m²) 22.92 17.14 32.47 0 
orosomucoid 
( g/L ) 
0.825 0.59 1.47 5 
Albumin 
( g/L ) 
40 28.7 47 9 
 
Sex women : 20 men : 14 0 
CDC Stage stage A or B : 29 stage C : 5 0 
Combivir 
coadministration 
Yes : 24 No : 10 0 
Good 
adherence 
Yes : 15 No : 11 8 
 
GENOTYPES Wild type Heterozygotes 
Homozygote 
mutants 
Nb missing 
values 
MDR1 exon 26 13 14 3 4 
MDR1 exon 21   22 5 4 3 
CYP3A4*1B 12 3 15 4 
CYP3A5*3  8 10 15 1 
CYP2C19*2 17 11 2 4 
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Table 2. Population PK parameters (and relative standard error in %) of 
nelfinavir and M8 from basic and final models 
 Basic model Final model 
 Estimate (RSE%) Estimate (RSE%) 
Structural model 
  
ka (h
-1
) 0.16 (25) 0.17 (27) 
Tlag (h
-1
) 0.83 (6) 0.82 (6) 
V/F (L) 176 (12) 191 (15) 
CL
T
/F (L/h) 51.3 (10) 52 (10) 
m
m
V
CL
(h
-1
) 
0.26 (40)  0.39 (35)  
k
em
 (h
-1
) 1.56 (38) 1.76 (30) 
m
m
V
CL
CYP2C19
β  
/ 0.98 (49) 
Statistical model   
ω
Ka
 (%) 
102 (37) 99 (42) 
FCL
T
ω  (%) 
50 (24) 49 (26) 
m
m
V
CL
ω  (%) 
65 (30) 59 (29) 
σ
NFV
 (%) 
31 (15) 32 (15) 
σ
M8
 (%) 
48 (22) 49 (22) 
r σ
NFV 
- σ
M8
 
/ 0.37 (40) 
 
 
 
 
 
 
 
 
 
 27 
 
Table 3 : Evolution of short term efficacy (during the 2 first weeks of treatment) and toxicity (from 4 weeks before to 4 
weeks after initiating the treatment) and significance of this evolution.   
 
Basal Value Value at week 2 or 4 Variation 
test 
 p 
 
Median Range Median Range Median Range 
 
HIV RNA 
(log
10
 copies/mL) 
4.86 2.95 – 6.04 2.93 1.60 – 4.57 1.80 1.25 – 2.73 
< 10
-4
 
Glycemia 
(mmol/L) 
4.95 3.70 – 6.20 4.85 4.20 – 6.80 0.21 -1.5 – 1.7 
0.05 
Total cholesterol 
(mmol/L) 
3.95 2.00 – 6.60 4.90 2.50 – 7.70 0.81 -1.49 – 3.7 
10
-4
 
HDL cholesterol 
(mmol/L) 
1.17 0.46 – 1.92 1.28 0.39 – 2.20 0.01 -1.53 – 1.69  
0.17 
Triglycerides 
(mmol/L) 
0.90 0.29 – 1.91 1.23 0.44 – 2.45 0.20 -0.68 – 1.17 
0.20 
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Legend for figures 
Figure 1 
Pharmacokinetic compartment model for nelfinavir and M8 plasma concentration 
after a nelfinavir oral dose D. Nelfinavir (in compartment 1) undergoes irreversible 
biotransformation to produce M8 (in compartment 2). 
F denotes bioavailability of nelfinavir, k
a
 the first-order absorption rate constant, V the 
nelfinavir distribution volume, k
e
 the nelfinavir elimination constant rate, k
m
 the first 
order metabolic rate constant, V
m
 the M8 distribution volume and k
em
 is the M8 
elimination rate constant.    
  
Figure 2 
Observed (points) and predicted (lines) plasma concentrations of nelfinavir (top) and 
M8 (bottom) vs. time: for CYP2C19 wild type, i.e. patients GG for CYP2C19*2 (empty 
points and dashed lines) and for CYP2C19 mutated patients, i.e. AG or AA for 
CYP2C19*2 (full points and lines). For nelfinavir, full and dashed lines are 
superposed. 
 
Figure 3 
Evaluation of the final model: comparison between the 5
th 
(dash line), 50
th
 (full line) 
and 95
th
 (dash line) percentile obtained from 1000 simulations and the observed data 
(points) for nelfinavir (top) and M8 (bottom).    
 
Figure 4 
Correlation between C
mean,N
 and the change in glycemia or triglycerides rate between 
week 4 and week -4.  
